Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
October 04, 2023 06:50 ET
|
Eton Pharmaceuticals
-- Expect Q1 2024 product launch ---- Nitisinone market estimated to be more than $50 million annually ---- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04,...
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 23, 2023 06:50 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 10, 2023 16:01 ET
|
Eton Pharmaceuticals
Total Q2 revenue of $12.0 million and net income of $4.6 millionProduct sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2023$21.6 million of cash on handLaunched Betaine...
Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 01, 2023 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
June 28, 2023 06:50 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., June 28, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Reports First Quarter 2023 Financial Results
May 11, 2023 16:01 ET
|
Eton Pharmaceuticals
Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022Launched Betaine AnhydrousManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., May 11,...
Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)
May 10, 2023 06:50 ET
|
Eton Pharmaceuticals
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Product is now available exclusively through Optime Care -- DEER PARK, Ill., May 10, 2023 ...
Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
May 03, 2023 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results
March 16, 2023 16:01 ET
|
Eton Pharmaceuticals
Q4 2022 revenue of $8.5 millionQ4 Product sales and royalty revenue up 220% from prior year and 9% from Q3Q4 positive net incomeManagement to hold conference call today at 4:30pm ET DEER PARK, Ill.,...
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
March 15, 2023 06:50 ET
|
Eton Pharmaceuticals
-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or...